On Friday, Shares of Pfizer Inc. (NYSE:PFE), lost -0.73% to $34.21.
Pfizer, declared that more than 20 abstracts counting new rheumatoid arthritis (RA) research for XELJANZ® (tofacitinib citrate) will be presented at the European League Against Rheumatism Annual Congress (EULAR 2015) June 10-15, Rome, Italy. Highlights comprise over six-years of safety and efficacy data from two long-term extension studies, real-world experience analyses, and clinical, patient-stated and radiographic efficacy outcomes with XELJANZ monotherapy, in addition to health economics outcomes research that comprise patient-preference data for XELJANZ in patients with RA. Notably, new results from the XELJANZ 11 mg once daily clinical pharmacology program will be presented during the Congress, demonstrating equivalence in key pharmacokinetic parameters to XELJANZ 5 mg twice daily.
“As the developer of XELJANZ, the first oral Janus kinase inhibitor for the treatment of moderate to severe RA, Pfizer is a leader in the research of this new class of medications. Emerging real-world experience complements the clinical profile of XELJANZ as established through our extensive global development program,” said Rory O’Connor, MD, senior vice president and head of Global Medical Affairs, Global Innovative Pharmaceuticals Business, Pfizer Inc. “We continue to focus on further characterizing the overall clinical profile of XELJANZ that comprises understanding the response of XELJANZ as monotherapy and by exploring a potential new once-daily formulation.”
These data — from clinical trials to real-world experience — further contextualize and expand the knowledge about the benefit:risk profile of XELJANZ in RA. XELJANZ is the first oral therapy in a new class of RA medicines, known as Janus kinase (JAK) inhibitors. Since the discovery of XELJANZ, the global clinical development program has accumulated efficacy and safety data with over six years of safety observations in long-term extension studies and more than 16,800 patient years of exposure across the program.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of Delta Air Lines, Inc. (NYSE:DAL), inclined 0.83% to $41.14, during its last trading session.
The experience at Los Angeles International Airport’s Terminal 5 recently reflects the style of the city and its travelers as Delta Air Lines (DAL) unveils the completion of a three-year terminal-wide refurbishment, counting the airline’s first private check-in lounge, Delta ONE at LAX. The $229-million Delta project was accomplished in partnership with Los Angeles World Airports (LAWA) and the City of Los Angeles.
“We’re fast on our way to becoming the airline of choice in Los Angeles by understanding what moves L.A. – its most prominent industries, its most desired destinations, and its discerning customers’ required amenities for travel,” said Delta President Ed Bastian. “Our investments in T5 now offer Angelenos a more premium airport experience, from check-in to take-off.”
Since 2009, Delta has been the fastest-growing carrier at LAX* and recently offers flights to the most important cities for L.A.’s entertainment, technology, health care, and automotive industries. The facility enhancements at Terminal 5 are part of the airline’s investment at LAX as Delta continues to grow its network in this global gateway.
Delta Air Lines, Inc. provides planned air transportation for passengers and cargo worldwide. The company operates in two segments, Airline and Refinery. Its route network comprises various gateway airports in Amsterdam, Detroit, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita.
Finally, Denbury Resources Inc. (NYSE:DNR), ended its last trade with -1.18% loss, and closed at $6.72, as oil prices are being driven into the red after Saudi Arabia said it is prepared to raise its oil output to new record highs. The Middle Eastern country is the world’s largest oil exporter.
Saudi Arabia is said to be in discussions with Indian buyers to supply more crude, which means the exporter could surpass its 10.3 million barrels produced per day record reached in May, Reuters Reports.
Denbury Resources Inc. operates as an independent oil and natural gas company in the United States. The company primarily focuses on improved oil recovery utilizing carbon dioxide. It holds properties located in Mississippi, Texas, Louisiana, and Alabama in the Gulf Coast region; and in Montana, North Dakota, and Wyoming in the Rocky Mountain region.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
